This company listing is no longer active
Horizon Therapeutics Valuation
Is H1ZN34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of H1ZN34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: H1ZN34 (R$58.24) is trading above our estimate of fair value (R$56.11)
Significantly Below Fair Value: H1ZN34 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for H1ZN34?
Other financial metrics that can be useful for relative valuation.
| What is H1ZN34's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$24.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7x |
| Enterprise Value/EBITDA | 29.9x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does H1ZN34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.8x | ||
BLAU3 Blau Farmacêutica | 7.6x | 10.9% | R$1.9b |
300122 Chongqing Zhifei Biological Products | 10.9x | 25.9% | CN¥84.7b |
BNTX BioNTech | 21.4x | -20.2% | US$21.3b |
HYPE3 Hypera | 11.2x | 14.1% | R$18.4b |
H1ZN34 Horizon Therapeutics | 47.8x | 20.2% | R$24.9b |
Price-To-Earnings vs Peers: H1ZN34 is expensive based on its Price-To-Earnings Ratio (47.8x) compared to the peer average (14.1x).
Price to Earnings Ratio vs Industry
How does H1ZN34's PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: H1ZN34 is expensive based on its Price-To-Earnings Ratio (47.8x) compared to the Global Biotechs industry average (30.1x)
Price to Earnings Ratio vs Fair Ratio
What is H1ZN34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 47.8x |
| Fair PE Ratio | 18.5x |
Price-To-Earnings vs Fair Ratio: H1ZN34 is expensive based on its Price-To-Earnings Ratio (47.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.